Streetbeat News

Stock Prices

BEKE

BILI

EDU

HTHT

TME

ZJYL

Chinese stocks are experiencing an uptick following China's decision to maintain its one-year and five-year loan prime rates for November. The positive sentiment is further bolstered by reports of Chinese regulators promising additional support for the property sector.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 4:12 pm

BRSH

Bruush Oral Care Inc. (NASDAQ:BRSH) shares surged on high volume after receiving a notice from Nasdaq for non-compliance with the minimum bid price requirement. The company's stock had closed below $1.00 for 30 consecutive days. Bruush has until May 13, 2024, to regain compliance, potentially through a reverse share split. Over 68 million shares traded, far exceeding the 100-day average of 1.62 million. BRSH shares are currently up 116% at 37 cents.

Portfolio Pulse from Erica Kollmann

November 20, 2023 | 4:11 pm

CRSP

CRISPR Therapeutics AG (NASDAQ:CRSP) stock is trading higher due to momentum from the UK MHRA's conditional marketing authorization for its CRISPR/Cas9 gene-edited therapy, CASGEVY, for sickle cell disease treatment. The therapy is authorized for patients 12 and older, with an estimated 2,000 eligible patients in the UK. Analysts are generally positive on CRSP, with an average price target of $84.45. CRSP shares have risen 42% over the past week and 85% over the past month, with a 10.3% increase to $74.85 on Monday morning.

Portfolio Pulse from Adam Eckert

November 20, 2023 | 4:10 pm

BBLG

Bone Biologics Corp (NASDAQ:BBLG) stock fell by 12% to $0.54 due to a public offering and private placement of over a million shares at $0.64 each, with additional unregistered warrants. H.C. Wainwright & Co. is managing the offering, expected to raise approximately $729,200 for clinical trials, patent expansion, and operational needs. The offering is set to close around November 20, with warrants exercisable at $0.52 for five and a half years. BBLG's 52-week range is $0.47 to $13.21.

Portfolio Pulse from Henry Khederian

November 20, 2023 | 4:06 pm

BLNK

HC Wainwright & Co. analyst Sameer Joshi has reiterated a Buy rating on Blink Charging (NASDAQ:BLNK) and maintained a $25 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 4:05 pm

NEM

Benzinga's options scanner detected significant options trades for Newmont (NYSE:NEM), with over 11 trades totaling $628,322 and 7 trades totaling $362,072. Market whales are targeting a price range of $30.0 to $35.0 for NEM options. The mean open interest is 1602.5 with a total volume of 4,609.00. Noteworthy bullish options activity includes trades and sweeps with expiration dates ranging from March 2024 to June 2024 and strike prices at $30 and $35. Newmont, the world's largest gold miner, is in the process of acquiring Newcrest, expected to close in November 2023. NEM's stock is currently trading at $36.48 with a neutral RSI, and its next earnings report is due in 94 days. An analyst from BMO Capital downgraded NEM to Outperform with a price target of $58.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 4:01 pm

BCRX

BioCryst Pharma (NASDAQ:BCRX) has received updated analyst ratings in the last quarter, with 1 bullish and 3 somewhat bullish ratings. The average 12-month price target for BCRX is $10.5, with a high of $12.00 and a low of $10.00, marking a 16.67% increase from the previous target of $9.00. Analysts base their ratings on financial predictions and company performance metrics.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 4:00 pm

UNH

Analysts have recently rated UnitedHealth Group (NYSE:UNH) with 1 bullish, 4 somewhat bullish, and 3 indifferent ratings. The average price target is $570.5, representing an upside from the current price of $534.02. This target has increased by 0.69% from the previous target of $566.60. Analyst ratings are based on predictions of a company's future earnings and revenue, and are updated quarterly or after major company events.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 4:00 pm

CABO

CHTR

CMCSA

DISH

A comparative study evaluates Comcast (NASDAQ:CMCSA) against its peers in the Media industry, analyzing financial metrics and market position. Comcast's P/E, P/B, and P/S ratios, ROE, EBITDA, gross profit, and revenue growth are compared to Charter Communications Inc, Cable One Inc, and DISH Network Corp. Comcast's P/E and P/B ratios suggest undervaluation, while its P/S ratio indicates potential overvaluation. The company's ROE, EBITDA, gross profit, and revenue growth are strong, indicating robust performance and market outperformance.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 4:00 pm

CHTR

Charter Communications (NASDAQ:CHTR) is evaluated against its competitors in the Media industry. It has a lower P/E ratio, suggesting growth potential, but a higher P/B ratio, indicating it may be overvalued in terms of book value. Its P/S ratio is below the industry average, suggesting it's undervalued based on sales. CHTR has a higher ROE and EBITDA than its peers, indicating efficient profit generation and strong cash flow. Revenue growth is positive compared to a negative industry average, showing market share gains. However, its gross profit is below the industry average, and it has a high debt-to-equity ratio, which could signal financial risk.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 4:00 pm